Patrick Ma, M.D., recently spoke at the World Non-Small-Cell Lung Cancer (NSCLC) Summit in Boston, with a presentation titled, "MET Targeted Therapy in NSCLC." Dr. Ma is the co-leader of the Sara Crile Allen and James Frederick Allen Comprehensive Lung Cancer Program at the Mary Babb Randolph Cancer Center,
The Allen Lung Cancer Program will also have a major presence at the 16th World Conference on Lung Cancer Sept. 6-9 in Denver. Several abstracts submitted by the program have been accepted for presentation.
Ma will make two major oral presentations and two mini oral presentations.
- The title of the major oral presentations are "Whole Exome Sequencing to Profile the Genomic Landscapes of Young Patients Diagnosed with NSCLC." WVU co-authors include Xiaoliang Wu, Wei Zhang and Scot Remick, M.D.
- The title of the second major oral presentation is "ALK-Rearranged NSCLC Adaptive Cell Plasticity with Early Onset TGFb2 Mediated Precision Drug Escape through PRC-2 Epigenetic Reprogramming." WVU co-authors include Wu and Zhang.
- One of the mini oral presentations is titled "Transcriptome-Metabolome Reprogramming of EGFR-Mutant NSCLC Contributes to Early Adaptive Drug-Escape via BCL-xL Mitochondrial Priming." WVU co-authors are Wu and Zhang.
- The second mini oral presentation is titled "Circulating Tumor Cells (CTC) Enrichment as Liquid-Biopsy for Molecular and Genomic Characterization in ALK-Rearranged (ALK+) Lung Cancer." WVU co-author is Zhang.
The program will also present a poster titled "Quantitative Immunofluorescence Based Expression Analysis in NSCLC Reveals Nuclear EZH2 as Poor Prognostic Biomarker." WVU authors include Sijin Wen, Ph.D., Zhang and Ma.
In addition, hematology oncology fellow graduate Abdul Rahman Alshehri, M.D., will make a mini oral presentation titled "Quantitative Mass Spectrometry Proteomics Identifies FRalpha and GARFT as Predictive Biomarkers in NSCLC Patients Treated With Pemetrexed." WVU’s Manish Monga, M.D., is last author, and Ma is co-author.
The World Conference on Lung Cancer is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies.
Brian Boone, M.D., surgical oncologist in the WVU Medicine Department of Surgery and WVU Cancer Institute, performed the state’s first hyperthermic intraperitoneal chemotherapy (HIPEC) infusion. This treatment delivers heated, sterilized chemotherapy to the abdomen as a treatment for cancer that has spread to the lining of the abdominal cavity, or peritoneum.
WVU Medicine Obstetrics and Gynecology has experienced remarkable growth over the last two years. By increasing its team of gynecologic oncologists and adding a nurse practitioner, physician assistant, and genetic counselor, the department has expanded its capability to serve gynecologic cancer patients.
The annual Holiday Celebration for WVU Medicine and Health Sciences employees will kick off on Thurs., Dec. 6, from 2 to 4 p.m. at The Market, located on the ground floor of the Health Sciences Center. The Market will close at 11:30 a.m. for the celebration.